Acurx Pharmaceuticals Llc ( (ACXP) ) has released its Q3 earnings. Here is a breakdown of the information Acurx Pharmaceuticals Llc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of antibiotics to address serious bacterial infections, operating within the healthcare sector.
In its latest earnings report for the quarter ending September 30, 2025, Acurx Pharmaceuticals highlighted a significant improvement in its cash position, reporting $5.9 million in cash, up from $3.7 million at the end of 2024. Despite this, the company continues to face challenges with ongoing net losses and an accumulated deficit.
Key financial metrics from the report include a net loss of $1.99 million for the three months ended September 30, 2025, compared to $2.82 million in the same period in 2024. Total operating expenses decreased significantly to $2.03 million from $2.83 million year-over-year, driven by reduced research and development costs. The company also raised approximately $7.8 million through various financing activities, including direct offerings and a warrant inducement agreement.
Looking forward, Acurx Pharmaceuticals remains focused on advancing its lead product candidate, ibezapolstat, through clinical trials. The management acknowledges the need for additional funding to sustain operations and achieve profitability, reflecting a cautious yet hopeful outlook for the company’s future in the biopharmaceutical industry.